From Autologous Transplant to Maintenance Therapy in Multiple Myeloma

Why do we use lenalidomide maintenance therapy post-stem cell transplant? In part eight of the Myeloma Series, The Fellow on Call discuss this question and others, including the following:

• What is the maintenance strategy for high-risk patients?
• What is the rationale for adding a proteasome inhibitor for high-risk patients?
• What data shows efficacy of doublet maintenance therapy for high-risk patients

They also do a deep dive into the FORTE trial and discuss the role of daratumumab in the maintenance setting.